accelerated approval

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

Inovio Pharmaceuticals faces a securities class action over allegedly false statements regarding manufacturing capabilities and regulatory prospects for INO-3107, following FDA's December 29 accelerated approval rejection.

Pomerantz Law Firm files class action against $INO for alleged securities fraud involving false manufacturing capability and FDA approval claims for INO-3107.

Law firm Levi & Korsinsky seeks investors in Inovio Pharmaceuticals securities class action alleging failure to disclose manufacturing delays and FDA's standard review decision.

Pomerantz files class action against Inovio Pharmaceuticals for alleged securities fraud related to false FDA approval statements and concealed manufacturing deficiencies.

Ascendis Pharma wins FDA approval for YUVIWEL, the first once-weekly treatment for pediatric achondroplasia. The therapy offers improved dosing convenience over existing options.

Inovio Pharmaceuticals faces class action lawsuit over alleged false statements regarding manufacturing defects and regulatory prospects after FDA rejected accelerated approval, causing 24% stock decline.

Inovio Pharmaceuticals faces securities lawsuit over false statements about manufacturing and regulatory prospects. FDA rejected accelerated approval for lead drug candidate, causing 24% stock drop.

Novartis's kidney drug Vanrafia shows sustained efficacy in slowing kidney function decline, supporting its path to full regulatory approval in 2026 for IgA nephropathy treatment.